Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

BACKGROUND: Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet
Autors principals: Williams, Bryan, MacDonald, Thomas M, Morant, Steve, Webb, David J, Sever, Peter, McInnes, Gordon, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Salsbury, Jackie, Mackenzie, Isla, Padmanabhan, Sandosh, Brown, Morris J
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2015
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4655321/
https://ncbi.nlm.nih.gov/pubmed/26414968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00257-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars